search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The development of a medication-related patient-reported experience measure to better inform reimbursement decision making and clinical practice


- candidate number24358
- NTR NumberNTR5860
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR17-mei-2016
- Secondary IDsMEC-2015-265 
- Public TitleThe development of a medication-related patient-reported experience measure to better inform reimbursement decision making and clinical practice
- Scientific TitleThe development of a medication-related patient-reported experience measure to better inform reimbursement decision making and clinical practice
- ACRONYMM-PREM study
- hypothesis
- Healt Condition(s) or Problem(s) studiedDrug trials, Patient education
- Inclusion criteriaIPF patients who 1) are prescribed Pirfenidone (current and new users), 2) can read and speak Dutch, and 3) are willing to participate.
aHUS patients who 1) are prescribed Eculizumab (current and new users), 2) can read and speak Dutch, and 3) are willing to participate.
- Exclusion criteriaN/a
- mec approval receivedno
- multicenter trialno
- randomisedno
- group[default]
- Type[default]
- Studytypeobservational
- planned startdate 1-nov-2014
- planned closingdate1-nov-2016
- Target number of participants150
- InterventionsN/A
- Primary outcomePerceived effectiveness
Perceived side-effects
Ease of use
Satisfaction
- Secondary outcomen/a
- TimepointsNew cases: Baseline (start of treatment), 3 and Prevalent cases: 3-monthly
- Trial web site
- status[default]
- CONTACT FOR PUBLIC QUERIES Merel Kimman
- CONTACT for SCIENTIFIC QUERIES Merel Kimman
- Sponsor/Initiator Maastricht University Medical Center (MUMC+)
- Funding
(Source(s) of Monetary or Material Support)
Dutch Lung Foundation, ZON-MW, The Netherlands Organization for Health Research and Development
- Publications
- Brief summaryBackground: Medications for rare diseases are often expensive and effectiveness can be uncertain due to small patient populations in clinical trials. This undermines value for money and increases the uncertainty facing the policy maker when considering such medications for reimbursement. The patientís evaluation of the effectiveness and acceptability of a therapy is not explicitly incorporated into the reimbursement decision making process. Yet, this evaluation may influence a range of outcomes such as uptake of, compliance with, and ultimately effectiveness of the medication. Hence, evaluation of patient experiences can promote efficient use of medications.

Aim: To develop a patient-reported outcome measure to better understand experiences and satisfaction with medications.

Methods: Two expensive medications that are under consideration for reimbursement in the Netherlands were used as case studies; 1) pirfenidone (esbriet) for patients with idiopathic pulmonary fibrosis, and 2) eculizumab (soliris) for patients with atypical haemolytic uraemic syndrome. Recognised methodology was used to develop the PESaM-questionnaire involving literature review, individual patient interviews (n=5), two focus groups (n=13), expert opinion (n=4), pre-testing of face and content validity using retrospective verbal probing (n=13), and evaluation of psychometric properties (n=175).

Results: Three measures were developed; a generic measure that can be used for any medication (16 items), a measure for pirfenidone (10 items) and one for eculizumab (12 items). The measures cover the following domains: perceived effectiveness, perceived side-effect, ease of use and satisfaction. Face and content validity of the three measures were considered good. Psychometric properties are under evaluation.

Conclusion: We developed three measures to assess patient experiences with medication in general and with pirfenidone and eculizumab specifically. In future these tools could be used to 1) inform reimbursement decision making, and 2) assist clinician and patient when making treatment choices.
- Main changes (audit trail)
- RECORD17-mei-2016 - 2-jul-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl